Navigation Links
Drug-Coated Balloons Slowly Making Their Mark on the European Interventional Cardiology Market
Date:11/3/2010

TORONTO, Nov. 3, 2010 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe. This market will continue to grow as physicians increasingly use the technology in cases where other devices may not be suitable.

Although drug-coated balloons lack extensive clinical data comparing their efficacy against other technologies, such as drug-eluting stents, they are being employed in patients where drug-eluting stents cannot be used. For example, patients who are not candidates for dual anti-platelet therapy are prevented from receiving a drug-eluting stent; in these patients a drug-coated balloon may be a viable treatment option. There is potential to use drug-coated balloons in combination with bare-metal stents to lower the risk of late stent thrombosis, which some believe is caused by the polymers holding the drug onto the stent platform. This way the patient would theoretically receive the benefits of the drug and the stent without the increased risk of late stent thrombosis.  

Drug-coated balloons are also being used to treat side branches of bifurcated lesions in the coronary arteries and for the treatment of instent restenosis. Although the practice of treating instent restenosis with another stent is currently being examined in clinical trials, physicians generally prefer not to perform this type of procedure.

"Although drug-coated balloons have been available in Europe as of 2007, they have experienced only minimal adoption so far," says Adrienne Ma, M.Sc., Analyst at MRG. "According to physicians interviewed by MRG, it is unlikely that interventional cardiologists will choose angioplasty alone when a stent could be placed. This market will continue to grow as the technology is used to treat patients in which other devices are not well suited. Physicians in Europe will continue to monitor data from clinical trials such as Eurocor's Valentines trial, Lutonix's PERVIDEO I trial, and B. Braun's PEPCAD trials, and positive results will further drive adoption."

MRG's European Markets for Interventional Cardiology Devices 2011 report includes analysis on France, Germany, Italy, and the UK. This report provides critical insight into trends that will fuel market growth for coronary stents, percutaneous transluminal coronary angioplasty balloon catheters, intravascular imaging catheters, pressure guidewires, optical coherence tomography, and accessory devices through 2015.  

About Millennium Research GroupMillennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com ), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Amy KrohnMillennium Research Group416-364-7776 ext. 101Chris Comfort
Decision Resources, Inc.
781-993-2597
'/>"/>

SOURCE Millennium Research Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents
2. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
3. STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children
4. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
5. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
6. Study Confirms: Your Hidden Food Allergies Are Making You Fat
7. Texas Childrens Hospital Discharges History-Making Teen Patient Again; This Time With a Transplanted Heart Replacing Mechanical Device
8. Teva Admits to Making False Statements in US Gianvi™ Label and Agrees to Corrective Measures
9. FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making
10. As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage
11. FDA Warns Three Companies to Stop Making Unproven Claims on Mouth Rinses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... phen Schmidt Join the Growing ... solutions for life sciences, today announced key new leaders have joined ... to a growing business.  This will bolster the company,s safety business ... joined ArisGlobal in the position of Vice President - Safety. George ...
(Date:4/28/2016)... FREMONT, Calif. , April 28, 2016 ... Enterprise Validation Lifecycle Management Solutions (VLMS) today ... products and services for sufferers of chronic ... management System to manage their corporate validation ... been seeking a software solution to manage ...
Breaking Medicine Technology:
(Date:4/28/2016)... Portland, Maine (PRWEB) , ... April 28, 2016 , ... ... of death and principal determinant of childhood mortality. This is particularly true in underdeveloped ... A lecture at the University of New England’s campus in Tangier, Morocco, will examine ...
(Date:4/28/2016)... ... 28, 2016 , ... Cognizin® Citicoline is one of three ... the Healthy Ageing category, Cognizin® is being considered for this prestigious honor due ... include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose a winner ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ ... Residency Network. The platform is scheduled to launch in July 2016 and will ...
(Date:4/28/2016)... ... April 28, 2016 , ... April, 28, 2016 – ... in Physical Medicine and Rehabilitation by Philadelphia Magazine. , Philadelphia Magazine’s annual Top ... surveying physicians and medical leadership across the country. These select individuals nominate outstanding ...
(Date:4/28/2016)... ... 28, 2016 , ... Starting today, households across the United ... Medical Prescription Assistance Program. They are customized to reflect the specific health needs ... a ready-to-use, state-themed card and, in the near future, material that highlights savings ...
Breaking Medicine News(10 mins):